Wordt geladen...
The Evolving Use of PI3 Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
B cells express four PI3K isoforms (p110α, p110β, p110γ, and p110δ) but have a unique dependence on p110δ for survival. The design of isoform-selective inhibitors is possible, and pharmacologic inhibition of p110δ is toxic to neoplastic CLL cells for both cell-intrinsic and cell-extrinsic reasons. I...
Bewaard in:
| Gepubliceerd in: | Hematol Oncol Clin North Am |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8239250/ https://ncbi.nlm.nih.gov/pubmed/34174987 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hoc.2021.03.009 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|